Сerium oxide nanoparticles increase the cytotoxicity of TNF-alpha in vitro
https://doi.org/10.17586/2220-8054-2018-9-4-537-543
Abstract
Cerium oxide nanoparticles (CeONP) were used as the modifying agent for the recombinant tumor necrosis factor-α and recombinant tumor necrosis factor-α-thymosin-α1 (rhTNF and rhTNF-T). A notable increase of the biological activity of proteins with antitumor effect was demonstrated. It was established that the cytotoxicity of rTNF-T+CeONP composite increases with the duration of exposure to 7 days. Modification of rTNF-T with cerium oxide nanoparticles provides a stronger and more stable cytotoxic effect in Hep-2, L929, and A-549 tumor cell lines.
About the Authors
O. Shydlovska
Zabolotny Institute of Microbiology and Virology NANU
Ukraine
Ukraine
Kyiv
E. Kharchenko
National University of Food Technologies
Ukraine
Ukraine
Kyiv
N. Zholobak
Zabolotny Institute of Microbiology and Virology NANU
Ukraine
Ukraine
Kyiv
A. Shcherbakov
Zabolotny Institute of Microbiology and Virology NANU
Ukraine
Ukraine
Kyiv
A. Marynin
National University of Food Technologies
Ukraine
Ukraine
Kyiv
O. Ivanova
Kurnakov Institute of General and Inorganic Chemistry
Russian Federation
Russian Federation
Moscow
A Baranchikov
Kurnakov Institute of General and Inorganic Chemistry
Russian Federation
Russian Federation
Moscow
V. Ivanov
Kurnakov Institute of General and Inorganic Chemistry; National Research Tomsk State University
Russian Federation
Russian Federation
Moscow
Tomsk
References
1. Goh C.R. Tumour necrosis factors in clinical practice. Ann Acad Med Singapore, 1990, 19 (2), P. 235–239.
2. Oberholzer A., Oberholzer C., Moldawer L.L. Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit Care Med., 2000, 28 (4), P. 3–12.
3. Klebanoff S.J., Vadas M.A., et al. Stimulation of neutrophils by tumor necrosis factor. J. Immunol., 1986, 136 (11), P. 4220–4225.
4. Yan C., Grimm W.A., et al. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am. J. Pathol., 2010, 176 (5), P. 2247–2258
5. VanCrevel R., Karyadi E., et al. Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation. J. Clin. Endocrinol. Metab., 2002, 87 (2), P. 758–763.
6. Gelin J., Moldawer L.L., Lonnroth C., Sherry B. Role of endogenous tumor necrosis factor- ¨ α and interleukin-1 for experimental tumor growth and the development of cancer cachexia. Cancer Res., 1991, 51, P. 415–421.
7. Tsai D.-H., Elzey S., et al. Tumor necrosis factor interaction with gold nanoparticles. Nanoscale, 2012, 4 (10), P. 3208.
8. Cui W., Cui Y., Zhao J., Li J. Fabrication of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)/ALG modified CaCO3 as drug carriers with the function of tumor selective recognition. J. Mater. Chem., 2013, 1 (9), P. 1326–1332.
9. Zholobak N.M., Mironenko A.P., et al. Cerium dioxide nanoparticles increase immunogenicity of the influenza vaccine. Antiviral research, 2016, 127, P. 1–9.
10. Shydlovska O., Zholobak N., et al. Response of interferon system to introduction of recombinant interferon modified with cerium dioxide nanoparticles. Proceedings of VIII International conference “Bioresources and viruses”, Kyiv, September 12–14, 2015, P. 51–54.
11. Shydlovska O., Spivak M., et al. Nanoparticles of cerium dioxide increase activity of recombinant tumor necrosis factor-alpha. Proceedings of XIV International Scientific Conference of Students, PhD Students & Young Scientists “Shevchenkivska Vesna: Biology”. Kyiv, April 23–24, 2016.
12. Ivanov V.K., Polezhaeva O.S., et al. Microwave-hydrothermal synthesis of stable nanocrystalline ceria sols for biomedical uses. Russ. J. Inorg. Chem., 2010, 55 (1), P. 1–5.
13. Tumor Necrosis Factor-α, Human, Recombinant: Certificate of Analysis. Promega Corporation Protocol https://www.promega.com/-/media/files/resources/protocols/product-information-sheets/g/tumor-necrosisfactor-alpha-human-recombinant-protocol.pdf?la=en.
14. Wang H.J., He W.Q., et al. Type I collagen gel protects murine fibrosarcoma L929 cells from TNFα-induced cell death. Biochem. Biophys. Res. Commun., 2015, 457 (4), P. 693–699.
15. Ye Y.C., Wang H.J., et al. RIP1-mediated mitochondrial dysfunction and ROS production contributed to tumor necrosis factor alpha-induced L929 cell necroptosis and autophagy. Int. Immunopharmacol, 2012, 14 (4), P. 674–682.
16. Myerson J., Green L., Warusawitharana M. Area under the curve as a measure of discounting. J. Exp. Anal. Behav., 2001, 76 (2), P. 235–243.
17. Shmelev V.A., Bunina Z.F., et al. Isolation of a group of hybrid proteins consisting of tumor necrosis factor alpha and thymosin alpha 1. Mol Gen Mikrobiol Virusol, 1995, 1, P. 9–14.
18. Shmelev V.A., Grigorev B.V., Mozharova T.I., Popov S.G. Thymosin alpha-1 and hybrid proteins consisting of tumor necrosis factor-alpha and thymosin alpha-1 enhance the efficacy of vaccination against the causative agent of plague. Zh. Mikrobiol. Epidemiol. Immunobiol., 1994, 4, P. 85–89.
19. Tsai D.-H., Elzey S., et al. Tumor necrosis factor interaction with gold nanoparticles. Nanoscale, 2012, 4 (10), 3208.
20. Flaherty N.L., Chandrasekaran A., et al. Comparative analysis of redox and inflammatory properties of pristine nanomaterials and commonly used semiconductor manufacturing nano-abrasives. Toxicol Lett., 2015, 239 (3), P. 205–215.
21. Kim M.S., Lee S.H., et al. Comparative Analyses of Complex Formation and Binding Sites between Human Tumor Necrosis Factor-alpha and its Three Antagonists Elucidate their Different Neutralizing Mechanisms. J. Mol. Biol., 2007, 374 (5), P. 1374–1388.
22. Nguyen V.H., Lee B.J. Protein corona: A new approach for nanomedicine design. Int. J. Nanomedicine, 2017, 12, P. 3137–3151.
Review
For citations:
Shydlovska O., Kharchenko E., Zholobak N., Shcherbakov A., Marynin A., Ivanova O., Baranchikov A., Ivanov V. Сerium oxide nanoparticles increase the cytotoxicity of TNF-alpha in vitro. Nanosystems: Physics, Chemistry, Mathematics. 2018;9(4):537-543. https://doi.org/10.17586/2220-8054-2018-9-4-537-543
Views:
8
Email this article 